IL272003A - Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication - Google Patents

Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication

Info

Publication number
IL272003A
IL272003A IL272003A IL27200320A IL272003A IL 272003 A IL272003 A IL 272003A IL 272003 A IL272003 A IL 272003A IL 27200320 A IL27200320 A IL 27200320A IL 272003 A IL272003 A IL 272003A
Authority
IL
Israel
Prior art keywords
intoxication
prevention
compounds
treatment
clostridial neurotoxins
Prior art date
Application number
IL272003A
Other languages
Hebrew (he)
Original Assignee
The Israel Institute Of Biological Res Iibr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Israel Institute Of Biological Res Iibr filed Critical The Israel Institute Of Biological Res Iibr
Priority to IL272003A priority Critical patent/IL272003A/en
Priority to PCT/IL2021/050040 priority patent/WO2021144794A1/en
Publication of IL272003A publication Critical patent/IL272003A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL272003A 2020-01-13 2020-01-13 Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication IL272003A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL272003A IL272003A (en) 2020-01-13 2020-01-13 Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication
PCT/IL2021/050040 WO2021144794A1 (en) 2020-01-13 2021-01-13 Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL272003A IL272003A (en) 2020-01-13 2020-01-13 Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication

Publications (1)

Publication Number Publication Date
IL272003A true IL272003A (en) 2021-07-29

Family

ID=76863925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272003A IL272003A (en) 2020-01-13 2020-01-13 Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication

Country Status (2)

Country Link
IL (1) IL272003A (en)
WO (1) WO2021144794A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
US7947717B2 (en) 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011022721A1 (en) 2009-08-21 2011-02-24 Microbiotix, Inc Inhibitors of botulinum neurotoxins
WO2013103780A1 (en) * 2012-01-06 2013-07-11 Trustees Of Boston University Compositions and methods to boost endogenous ros production from bacteria
US20180147223A1 (en) 2016-11-29 2018-05-31 Prime Bio, Inc Botulinum neurotoxin inhibitors

Also Published As

Publication number Publication date
WO2021144794A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
EA202091389A1 (en) PROBIOTIC-BASED COMPOSITION AND ITS APPLICATION
EP3592374C0 (en) COMPOSITION OF SUPEROXIDE DISMUTASE FROM BACILLUS AMYLOLIQUEFACIENS GF423 STRAIN FOR PROVIDING ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA
MX2009007410A (en) Inhibitors of d-amino acid oxidase.
WO2011011330A3 (en) Inhibitors of d-amino acid oxidase
MX2017012545A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
IL312583A (en) Composition for treatment and prevention of covid-19
KR102217525B9 (en) Lactobacillus for the prevention or treatment of periodontitis and its use
GB202005097D0 (en) Treatment and/or prevention of covid-19 infection
MX2017012535A (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections.
PL3848024T3 (en) Compositions comprising amino acids for prevention and/or treatment of cancer
EP4225923A4 (en) Compositions and methods for the prevention and/or treatment of covid-19
ZA202207728B (en) Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
MX2017014080A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
IL272003A (en) Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication
IL273297A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
WO2020139020A3 (en) Kimchi for preventing or treating helicobacter pylori-associated diseases
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
SG11202008791UA (en) Agent for prevention and/or treatment of pseudomonas aeruginosa infection
BR112019002023A2 (en) prevention or treatment of antifungal infections vectorized by probiotic bacteria
EP4149420C0 (en) Protease formulation for treatment of microbial infections
GB202109624D0 (en) Composition comprising nutgall extract and fraxin as active ingredient for improvement of cognitive ability and for prevention or treatment of dementia
MX2022000433A (en) Fusion toxin proteins for treatment of diseases related to cmv infections.
EP4648779A4 (en) Use of compound 1 in treatment or prevention of atopic dermatitis
EP4401738A4 (en) MEDICINES FOR THE PREVENTION AND/OR TREATMENT OF DRY EYE